| Dr Saleh Rachidi, MD, PHD | |
|
8100 Boone Blvd Ste 230, Vienna, VA 22182-2642 | |
| (703) 495-5555 | |
| Not Available |
| Full Name | Dr Saleh Rachidi |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Location | 8100 Boone Blvd Ste 230, Vienna, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447609615 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 0101277532 (Virginia) | Primary |
| Entity Name | Michael Paltiel Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013175165 PECOS PAC ID: 2163595729 Enrollment ID: O20080717000520 |
News Archive
Continuing a proud tradition, BioTek Instruments will receive the 2015 Governor's Excellence in Worksite Wellness Award, presented by the Governor's Council on Physical Fitness and Sports.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Saleh Rachidi, MD, PHD 8100 Boone Blvd Ste 230, Vienna, VA 22182-2642 Ph: () - | Dr Saleh Rachidi, MD, PHD 8100 Boone Blvd Ste 230, Vienna, VA 22182-2642 Ph: (703) 495-5555 |
News Archive
Continuing a proud tradition, BioTek Instruments will receive the 2015 Governor's Excellence in Worksite Wellness Award, presented by the Governor's Council on Physical Fitness and Sports.
Our modern epidemic of obesity has led to an alarming rise in the incidence of diabetes. More than 382 million people on the planet suffer from diabetes, predominantly type-2 diabetes. For these people, blood sugar surges - glucose spikes after meals - can be life threatening, leading to cardiovascular complications.
CTI BioPharma Corp. announced today that pacritinib has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of intermediate and high risk myelofibrosis, including but not limited to patients with disease related thrombocytopenia, patients experiencing treatment emergent thrombocytopenia on other JAK2 therapy or patients who are intolerant to or whose symptoms are sub-optimally managed on other JAK2 therapy.
Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.
Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
› Verified 5 days ago
Dr. Kelley Pagliai Redbord, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 243 Church St Nw, Suite 200-c, Vienna, VA 22180 Phone: 703-938-5700 Fax: 703-938-4467 | |
Dr. Marina Shuster Jungwirth, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2236c Gallows Rd, Fl 2, Vienna, VA 22182 Phone: 443-351-3376 | |
Dr. William Samuel Sawchuk, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8320 Old Courthouse Rd, Suite 303, Vienna, VA 22182 Phone: 703-532-7211 Fax: 703-534-2874 | |
Sylvia M Suarez, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2236c Gallows Rd, Second Floor, Vienna, VA 22182 Phone: 703-827-7008 Fax: 703-827-7011 | |
Dr. Gayle Debra Masri-fridling, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 8320 Old Courthouse Rd, Suite 303, Vienna, VA 22182 Phone: 703-532-7211 Fax: 703-534-2874 | |
Dr. Naiem Tony Issa, M.D., PH.D. Dermatology Medicare: Medicare Enrolled Practice Location: 8301 Old Courthouse Rd, Vienna, VA 22182 Phone: 703-442-0300 Fax: 703-442-0337 |